KLOW is a vendor-blended stack of GHK-Cu, BPC-157, TB-500, and KPV — the GLOW blend plus KPV — that the community runs mostly for tissue and injury repair and general recovery, with roughly three-quarters of reports positive. People most commonly inject 4 mg a day, though reported doses span 15 mcg to 40 mg, and sleep changes, GI upset, and fluid retention each surface only occasionally in community reports. The blend carries no FDA approval and the supporting research is preclinical, so all human use is off-label or compounded.
Data last updated
Measured on 4 of 6 axes
Evidence shape
KLOW currently exists exclusively within the realm of animal-only research, with no published human trials or clinical data available to support its use. The existing literature is limited to preclinical and mechanistic studies, providing no evidence of efficacy or safety in human subjects. Because there are no registered trials or completed human studies, the therapeutic profile remains entirely theoretical and lacks the necessary data to establish clinical utility.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How KLOW is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most community reports (49 of 80) don't specify a dosing schedule; among those that do, daily dosing around 4 mg subQ is most common, with a smaller group running weekly doses around 5 mg.